BICILLIN C-R (penicillin g benzathine and penicillin g procaine) by Pfizer is mechanism of action penicillin g exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. Approved for the treatment of infections, the treatment of the following in pediatric patients: moderately severe to severe infections of the upper-respiratory tract, scarlet fever and 3 more indications. First approved in 1953.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
BICILLIN C-R is a fixed-dose combination injectable containing penicillin G benzathine and penicillin G procaine, approved in 1953. It is indicated for treatment of moderately severe to severe infections including upper-respiratory tract infections, scarlet fever, erysipelas, and skin/soft-tissue infections caused by susceptible streptococci. The drug works through bactericidal inhibition of bacterial cell-wall peptidoglycan biosynthesis.
Legacy product with minimal Part D spending ($35K in 2023) and declining patient base signals team restructuring and transition planning ahead of loss of exclusivity.
Mechanism of Action Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable resulting in death of the…
Worked on BICILLIN C-R at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moZero linked jobs and minimal commercial activity ($35K Part D spend, 78 claims) indicate BICILLIN C-R is a legacy asset with limited career momentum at Pfizer. Roles supporting this product focus on defending market share, managing manufacturing transitions, and preparing for generic competition rather than growth or innovation.